Industry News and Headlines

Promatix EGFR×EphA2 Bispecific ADC Exerts Antitumor Activity

Today’s brief highlights four pre‑clinical advances: Paratus Sciences unveiled PS‑1001, a pan‑inflammasome blocker targeting IL‑1β and IL‑18 for hidradenitis suppurativa; researchers identified the SCAN circuit as a core pathway disrupted in Parkinson’s disease; RX‑10616 demonstrated enhanced radiotherapy response in head‑and‑neck squamous cell carcinoma; and CROI 2026 underscored neurodegeneration as a growing challenge for aging people living with HIV. Each development signals potential therapeutic breakthroughs across inflammation, neuro‑degeneration, oncology, and infectious disease fields.